1. Hepcidin predicts response to IV iron therapy in patients admitted to the intensive care unit: a nested cohort study
- Author
-
Edward Litton, Stuart Baker, Wendy Erber, Shannon Farmer, Janet Ferrier, Craig French, Joel Gummer, David Hawkins, Alisa Higgins, Axel Hofmann, Bart De Keulenaer, Julie McMorrow, John K. Olynyk, Toby Richards, Simon Towler, Robert Trengove, Steve Webb, on behalf of the IRONMAN Study investigators, and the Australian and New Zealand Intensive Care Society Clinical Trials Group
- Subjects
Anaemia ,Critical care ,Hepcidin ,Intravenous iron ,Red blood cell transfusion ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract Background Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement. Methods We conducted a prospective observational study nested within a multicenter randomized controlled trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western Australia. Critically ill patients with haemoglobin (Hb) of
- Published
- 2018
- Full Text
- View/download PDF